Top 5 mRNA Vaccine and Therapeutics Companies

Published: May 2026

Messenger ribonucleic acid (mRNA) is a form of single-stranded ribonucleic acid (RNA) that plays a crucial role in conveying genetic information necessary for protein production. The mRNA carries the genetic instructions for protein synthesis from a segment of DNA to the ribosomes, where these instructions are translated and developed into functional proteins. Recently, mRNA therapeutics and mRNA vaccines have emerged as a promising alternative to traditional treatment methods. Following the emergence of the coronavirus preventive vaccines, mRNA Vaccine and Therapeutics Market has gained substantial attention, evolving into a groundbreaking class of drugs for treating infectious diseases, along with a range of other conditions such as, cancer, genetic disorders, and additional ailments.

To date, four mRNA-based vaccines have been authorized, with several other candidates currently under evaluation as potential therapies. Furthermore, the overall success of mRNA therapies and vaccines in combating COVID-19 has piqued the interest of numerous investors, particularly in small and emerging biotechnology companies focused on mRNA.

With the increasing mRNA Vaccine and Therapeutics Market growth in diverse therapeutic applications, researchers and healthcare professionals are actively looking for cost-effective alternatives for mRNA synthesis and manufacturing. This growing demand presents substantial opportunities for contract manufacturing organizations to expand their services and contribute to the industry in the coming years.

Roots Analysis has conducted an exhaustive study on mRNA Vaccine and Therapeutics Market featuring the current market landscape and future opportunity for the companies engaged in healthcare, over a span of next 9 years.

Top Five Leading mRNA Vaccine and Therapeutics Manufacturers

BioNTech
Moderna
Curevac
Providence Therapeutics
Walvax Biotechnology

The figure below highlights the top five mRNA manufacturers:

Top 5 mRNA Vaccine and Therapeutics Companies

Interested in exploring all ~50 players offering mRNA related services and kits, along with their recent initiatives?

Discover Below the Details on Top 5 mRNA Vaccine and Therapeutics Manufacturers

Let us dive deep into the details of the top mRNA vaccine companies 2026. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. BioNTech

Company Overview

BioNTech, a pioneering biopharmaceutical company, was founded in 2008 by Dr. Ugur Sahin and Dr. Ozlem Tureci. The company is focused on developing personalized immunotherapies for cancer and infectious diseases. Further, BioNTech's groundbreaking mRNA technology platform has garnered significant global attention, particularly during the COVID-19 pandemic, for its collaboration with Pfizer to develop one of the first authorized mRNA vaccines against the virus. Following the pandemic, BioNTech continued to advance its diverse pipeline of mRNA-based therapeutics and cancer immunotherapies, aiming to revolutionize the treatment landscape and improve patients' lives worldwide.

List of Drug Manufactured, Stage of Development, Therapeutic Area, Type of Molecule and Route of Administration

The section provides information on the various drugs being manufactured by BioNTech, along with details on stage of development, therapeutic area, type of molecule and route of administration dedicated to mRNA.

Drug: COMIRNATY
Stage of Development: Commercial
Route of Administration: Intramuscular
Type of Molecule: SARS-CoV-2 Spike Protein
Therapeutic Area: Infectious Diseases

Recent Developments

In June 2025, BioNTech announced a strategic transaction to acquire CureVac through an all-stock public exchange offer, strengthening its mRNA cancer immunotherapy pipeline and complementing CureVac’s mRNA design, delivery, and manufacturing expertise to advance BioNTech’s oncology strategy.

To know more about the recent initiatives of BioNTech and other mRNA Companies, access full report.

2. Moderna

Company Overview

Moderna stands at the forefront of mRNA medicine innovation. By advancing mRNA technology, Moderna is redefining the production of medicines and revolutionizing the treatment and prevention of diseases for everyone. With over a decade of experience at the convergence of science, technology, and health, the company has created medicines with unparalleled speed and efficiency, including one of the first and most effective vaccines for COVID-19.

Moderna's mRNA platform has facilitated the creation of treatments and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions. Boasting a distinct culture and a worldwide team motivated by the values and principles of Moderna to responsibly enhance the future of human health, the company aims to make the most significant positive impact through mRNA medicines.

List of Drug Manufactured, Stage of Development, Therapeutic Area, Type of Molecule and Route of Administration

Drug: Spikewax, mNEXSPIKE, mRESVIA
Stage of Development: Commercial, Commercial, Commercia
Route of Administration: Intramuscular, Intramuscular, Intramuscular
Type of Molecule: SARS-CoV-2 Spike Protein, SARS-CoV-2 Spike Protein, Prefusion F Glycoprotein
Therapeutic Area: Infectious Diseases, Infectious Diseases, Infectious Diseases

Recent Developments

In September 2025, Moderna fully operationalized its new UK manufacturing and R&D facility in Harwell, Oxfordshire, producing up to 100 million mRNA vaccine doses annually with a scalable capacity of 250 million, supporting UK health resilience and pioneering research into mRNA therapeutics.

To know more about the recent initiatives of Moderna and other mRNA Companies, access full report.

3. Curevac

Company Overview

CureVac is an innovative international biotech firm established in 2000 to promote the use of mRNA technology in human medicine. Over more than twenty years of developing, refining, and producing this adaptable biological agent for medical purposes, CureVac has launched and enhanced critical technologies that were vital for creating mRNA vaccines against COVID-19 and is currently preparing to apply mRNA in new therapeutic fields with significant unmet needs.

CureVac is utilizing mRNA technology, along with advanced omics and computational methods, to design and produce both off-the-shelf and personalized cancer vaccine candidates. It is also engaged in developing preventive vaccines and treatments that stimulate the human body to generate its own therapeutic proteins.

List of Drug Manufactured, Stage of Development, Therapeutic Area, Type of Molecule and Route of Administration

Drug: CV0601/CV0701
Stage of Development: Phase II
Route of Administration: Intramuscular
Type of Molecule: SARS-CoV-2 Spike Protein
Therapeutic Area: Infectious Diseases

Recent Developments

In August 2025, CureVac and GSK settled all pending U.S. patent litigation with BioNTech and Pfizer over mRNA COVID-19 vaccines, receiving USD 740 million and future royalties, while granting non-exclusive manufacturing licenses ahead of BioNTech's planned USD 1.25 billion acquisition of CureVac announced in June 2025.

To know more about the recent initiatives of Curevac and other mRNA Companies, access full report.

4. Providence Therapeutics

Company Overview

Providence Therapeutics is a clinical-stage biotechnology company specializing in the development of mRNA medicines through three integrated platforms: an mRNA Medicines Platform, the proprietary INTENT Lipid Nanoparticle (LNP) Platform, and a Manufacturing Platform. The company’s mRNA and INTEN LNP platforms provide an end-to-end solution for designing codon-optimized, ultrapure mRNA formulated within application-optimized lipid nanoparticles.

Providence's scalable and efficient platform demonstrates advanced capabilities in mRNA design, manufacturing, formulation, and targeted delivery to specific organs and tissues, supporting a broad array of therapeutic applications. This integrated ecosystem supports rapid and robust development from research through clinical to commercial scales.

List of Drug Manufactured, Stage of Development, Therapeutic Area, Type of Molecule and Route of Administration

Drug: PTX-COVID19-B
Stage of Development: Phase II
Route of Administration: Intramuscular
Type of Molecule: SARS-CoV-2 Spike Protein
Therapeutic Area: Infectious Diseases

Recent Developments

In January 2025, Providence Therapeutics reported that its bivalent and tri-antigenic mRNA vaccines had demonstrated broad, durable immune protection—leveraging strong T cell responses and multi-antigen design—to potentially outpace rapidly mutating respiratory viruses like COVID-19.

To know more about the recent initiatives of Providence Therapeutics and other mRNA manufacturers, access full report.

5. Walvax Biotechnology

Company Overview

Walvax Biotechnology, founded in 2001, is one of China’s leading vaccine producers, specializing in the research, development, manufacturing, and distribution of safe, effective, and high-quality vaccines. Headquartered in Kunming, Yunnan Province, the company went public in 2010 and has since expanded from traditional vaccine programs to innovative platforms. Guided by its vision to be a domestic pride and global pioneer in the vaccine industry, Walvax is committed to delivering efficacious, innovative, and affordable vaccines that protect people worldwide and promote healthier lives.

List of Drug Manufactured, Stage of Development, Therapeutic Area, Type of Molecule and Route of Administration

Drug: ARCoV
Stage of Development: NDA/EUA
Route of Administration: Intramuscular
Type of Molecule: SARS-CoV-2 Spike Protein
Therapeutic Area: Infectious Diseases

Recent Developments

In March 2025, Walvax Biotechnology presented Phase IV safety data on its 23-valent pneumococcal vaccine, with executives leading discussions on global vaccine innovation and capacity growth alongside DCVMN, PATH, and the Gates Foundation at Vaccine Innovation Forum World in Shanghai.

To know more about the recent initiatives of Walvax Biotechnology and other mRNA Companies, access full report.

What About Other mRNA Manufacturers Companies Around the World?

The above article features the top five mRNA companies selected from a pool of around 50 manufacturers that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: